Skip to main navigation

Top Navigation

Publications
Newsroom
Investors
Blog
Careers
Contact Us

mRNA Technology
Modalities
Pipeline
- Clinical Trials
- Therapeutic Areas
Citizenship
- Corporate Responsibility
About Us

Investors

IR Navigation

Overview
Stock Information
Corporate Governance
SEC Filings
Events & Presentations
Press Releases
Shareholder Resources
Statements & Perspectives

Investor Relations

Day High

Day Low

Volume

8:03 AM EST
November 26, 2020

Copyright West LLC.
Minimum 15 minutes Delayed.

Press Releases

November 25, 2020

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

November 17, 2020

European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

November 17, 2020

Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use

View All Press Releases

Events

No events are currently scheduled.

View All Events

Presentations

Corporate Presentation

Annual R&D Day Presentation

Annual Science Day Presentation

Pipeline Program Detail

IR Contact

IR@modernatx.com

Email Alerts

Click Here to have company news delivered to your inbox

mRNA Technology
Modalities
Pipeline
Citizenship
About Us

Publications
Newsroom
Investors
Blog
Careers
Contact Us

Facebook
Twitter
Youtube
LinkedIn

Footer Menu - Bottom

© 2020 Moderna, Inc.
Privacy Policy
Join our Mailing List
Terms of Use

×

You are now leaving investors.modernatx.com, a website provided by Moderna. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. The content displayed on external websites is not controlled by Moderna, and Moderna assumes no responsibility for the information or statements on such external websites.